Altogether these results suggest that BRCA1-deficient ovarian cancer cells resistant to Olaparib trigger an overall negative regulation of the immune response that has a relationship with the presence of cytosolic cytoplasmic ssDNA and activation of the STINGs (Stimulator of Interferon Genes) pathway. The gene discussed is BRCA1; the disease is ovarian carcinoma.